EZH2 and lymphoma: According to current evidence, the effect of EZH2-H3K27me3 pathway to platinum resistance was heterogeneous in different cancer types: EZH2/H3K27me3 contributed to platinum resistance in ovarian cancer, cervical cancer, colorectal cancer, lung cancer and gastric cancer while sensitizing osteosarcoma and lymphoma to platinum treatment.